Janet Dillione
Known title: DirectorCIK: 0001489798
Associated companies
Transaction History
| CRMD | ▲ Buy | Option Exercise | 48,909 | — | 9/18/2026 | View on chart |
| CRMD | ▲ Buy | Grant | 30,453 | $0 | 1/26/2026 | View on chart |
| CRMD | ▼ Sell | Open Market | 10,000 | $69K | 1/21/2026 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 19,000 | $181K | 12/9/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 15,000 | $84K | 12/9/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 34,000 | $408K | 12/9/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 12,210 | $49K | 12/2/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 15,124 | $67K | 12/2/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 19,323 | $69K | 12/2/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 46,657 | $467K | 12/2/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 8,000 | $23K | 11/24/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 7,790 | $31K | 11/24/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 4,876 | $22K | 11/24/2025 | View on chart |
| CRMD | ▲ Buy | Option Exercise | 5,677 | $20K | 11/24/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 26,343 | $262K | 11/24/2025 | View on chart |
| CRMD | ▼ Sell | Open Market | 30,000 | $343K | 11/14/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 25,000 | $0 | 1/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.